Schonfeld Strategic Advisors LLC Coherus Bio Sciences, Inc. Transaction History

Schonfeld Strategic Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.17 - $13.87 $54,592 - $105,606	7,614 Added 24.05%	39,268 $376,000
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $185,492 - $418,782	31,654 New	31,654 $229,000
Q1 2022 May 16, 2022	SELL	$10.92 - $16.41 $251,160 - $377,430	-23,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$15.81 - $18.99 $363,630 - $436,769	23,000 New	23,000 $367,000
Q2 2021 Aug 16, 2021	SELL	$12.95 - $15.41 $247,383 - $294,377	-19,103 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.42 - $21.39 $275,465 - $408,613	19,103 New	19,103 $279,000
Q2 2020 Aug 14, 2020	SELL	$14.43 - $19.16 $360,057 - $478,080	-24,952 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$11.67 - $22.53 $417,739 - $806,483	-35,796 Reduced 58.93%	24,952 $405,000
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $992,014 - $1.3 Million	60,748 New	60,748 $1.09 Million
Q3 2019 Nov 14, 2019	SELL	$16.3 - $23.37 $1.3 Million - $1.86 Million	-79,600 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$13.1 - $22.1 $2.32 Million - $3.91 Million	-177,100 Reduced 68.99%	79,600 $1.76 Million
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $2.15 Million - $3.98 Million	256,700 New	256,700 $3.5 Million

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.